A father from Scotland who is living with motor neurone disease (MND) is supporting a campaign to raise £350,000 to fund a clinical trial for a ‘miracle drug’ that aims to reverse the effects of the condition. Mark Sommerville has joined forces with Tony Lockett and Andy Whiting from Nevrargenics, the company behind the drug Ellorarxine. The drug has received approval from the UK MHRA to commence its first clinical trial in MND and Frontotemporal dementia patients.
To expedite the clinical trial process and start crucial manufacturing, the campaign needs to raise £350,000 for the early-phase work necessary to make Ellorarxine accessible to patients. Mark, who received his devastating diagnosis in October and was given 18 months to live, is backing Nevrargenics’ initiative. He emphasised the urgent need for effective treatments for MND, a life-limiting illness with currently no cure.
Whiting, the CEO of Nevargenics, stated that their goal is to introduce Ellorarxine to MND patients by the end of 2025. Mark established the Mark Sommerville Foundation to support research efforts and advocates for increased government funding to find a cure for MND. Last month, Prime Minister Keir Starmer singled out Mark for support, recognising his efforts and those of rugby league star Kevin Sinfield, who raised an additional million for MND sufferers.
Whiting highlighted the urgency of securing funding in the current challenging UK investment market to accelerate the drug’s availability to patients. He emphasised that the timely allocation of funds could potentially save several months, crucial for MND patients given their average lifespan of 24 months.
Mark’s story underscores the arduous battle faced by MND patients and the hope that groundbreaking treatments like Ellorarxine bring to those affected by this debilitating disease. The campaign’s mission to advance the clinical trial of this promising drug signifies a beacon of hope for individuals like Mark and their families, emphasising the importance of continued research and support for MND patients.
In summary, the article discusses a heartfelt initiative led by a father battling MND to raise funds for a clinical trial of a potential ‘miracle drug’ that could reverse the effects of the disease. The campaign’s urgency in securing funding highlights the critical need for innovative treatments for MND patients and underscores the importance of ongoing research and support in the fight against this devastating illness.